These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10898107)

  • 1. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.
    Ozdemir V; Kalow W; Tang BK; Paterson AD; Walker SE; Endrenyi L; Kashuba AD
    Pharmacogenetics; 2000 Jul; 10(5):373-88. PubMed ID: 10898107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test.
    Lown KS; Kolars JC; Thummel KE; Barnett JL; Kunze KL; Wrighton SA; Watkins PB
    Drug Metab Dispos; 1994; 22(6):947-55. PubMed ID: 7895614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
    Lamba JK; Lin YS; Thummel K; Daly A; Watkins PB; Strom S; Zhang J; Schuetz EG
    Pharmacogenetics; 2002 Mar; 12(2):121-32. PubMed ID: 11875366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
    Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
    J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.
    Kenworthy KE; Bloomer JC; Clarke SE; Houston JB
    Br J Clin Pharmacol; 1999 Nov; 48(5):716-27. PubMed ID: 10594474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
    Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
    J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
    Kharasch ED; Jubert C; Senn T; Bowdle TA; Thummel KE
    J Clin Pharmacol; 1999 Jul; 39(7):664-9. PubMed ID: 10392320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
    Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
    Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Gorski JC; Wainer IW; Schwartz JB
    Clin Pharmacol Ther; 1999 Jul; 66(1):40-50. PubMed ID: 10430108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions.
    Lehmann JM; McKee DD; Watson MA; Willson TM; Moore JT; Kliewer SA
    J Clin Invest; 1998 Sep; 102(5):1016-23. PubMed ID: 9727070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
    Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
    J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
    Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M
    Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.
    Damkier P; Hansen LL; Brosen K
    Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acid 305 determines catalytic center accessibility in CYP3A4.
    Fowler SM; Riley RJ; Pritchard MP; Sutcliffe MJ; Friedberg T; Wolf CR
    Biochemistry; 2000 Apr; 39(15):4406-14. PubMed ID: 10757990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
    He P; Court MH; Greenblatt DJ; Von Moltke LL
    Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.
    Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Bacchi CE; Marsh CL; McVicar JP; Barr DM; Perkins JD
    J Pharmacol Exp Ther; 1994 Oct; 271(1):557-66. PubMed ID: 7965756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6',7'-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein.
    Edwards DJ; Fitzsimmons ME; Schuetz EG; Yasuda K; Ducharme MP; Warbasse LH; Woster PM; Schuetz JD; Watkins P
    Clin Pharmacol Ther; 1999 Mar; 65(3):237-44. PubMed ID: 10096255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase.
    Hu M; Li Y; Davitt CM; Huang SM; Thummel K; Penman BW; Crespi CL
    Pharm Res; 1999 Sep; 16(9):1352-9. PubMed ID: 10496649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
    Lin YS; Dowling AL; Quigley SD; Farin FM; Zhang J; Lamba J; Schuetz EG; Thummel KE
    Mol Pharmacol; 2002 Jul; 62(1):162-72. PubMed ID: 12065767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.